CCRM Nordic, the Nordic centre for advanced therapy medicinal products (ATMPs), and Cellectricon, a Swedish company advancing neuroscience drug discovery through innovative in vitro technologies, today announced a strategic collaboration to establish and scale robust manufacturing methods for Cellectricon’s stem cell–based models.
By combining Cellectricon’s deep expertise in neuroscience and stem cell technologies with CCRM Nordic’s end-to-end capabilities in ATMP process development and manufacturing capabilities, as well as expertise in stem cells, the partnership aims to establish scalable, reproducible manufacturing approaches for complex cell models used in early drug discovery, safety testing and therapeutic development.
“Partnering with CCRM Nordic allows us to refine and scale up the manufacturing of our stem cell models, taking them from advanced research tools to standardized, reproducible systems ready for broader adoption across the life science sector,” says Mattias Karlsson, CEO of Cellectricon. “It’s a major step forward that strengthens our ability to support clients from discovery through early development.”
“Cellectricon’s stem cell-based models have significant potential to improve predictability in early drug discovery and safety assessment,” said Fredrik Wessberg, CEO of CCRM Nordic. “Through this collaboration, we can apply our stem cell and manufacturing expertise to ensure the quality of tools that enable the development of better, safer therapies for patients.”